Loading...
Variables Influencing 6-Month Relapse in Early-Stage Hepatocellular Carcinoma After Radiofrequency Ablation
Зохиогч
Он
2024 оны гуравдугаар сарын 12
Төрөл
journal article
Хэвлэгч
Mongolian National University of Medical Sciences
Journal
Central Asian Journal of Medical Sciences
Volume
10
Issue
1
Start Page
15
End Page
25
ISSN
2413-8681
2414-9772
Хураангуй
Objectives: Hepatocellular carcinoma (HCC) emerged as a global health concern in 2020, ranking as the sixth most diagnosed cancer and the third leading cause of cancer-related death. This study analyzed predictors of 6-month relapse in early-stage HCC patients after Radiofrequency Ablation (RFA). Methods: This retrospective study, from January 1, 2018, to December 31, 2022, meticulously explored ablation methods for early-stage HCC treatment. Data collection included a 6-month relapse definition, demographic details, and tumor-related variables. Results: Over five years, 483 participants underwent RFA for early-stage HCC, presenting diverse demographic and tumor-related profiles. Significant associations were found between relapse and factors such as gender, smoking, alcohol use, tumor size, specific tumor locations, and pre-treatment AST levels. Notably, 6.8% of participants experienced relapse within six months. In the multivariate analysis, adjusting for confounders, smoking (p = 0.014), tumor size > 3cm (p < 0.001), tumor location S2 (p < 0.001), and pre-treatment AST levels (p = 0.015) remained significant predictors. Conclusion: This study sheds light on the complex dynamics of 6-month relapse in early-stage HCC patients, emphasizing the significance of predictors such as smoking, tumor size, tumor location, and pre-treatment AST levels.